Related Experiment Video
Updated: Oct 13, 2026
A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo
Published on: January 10, 2025
Anemia in inflammatory bowel disease - the role of recombinant human erythropoietin
1Department of Gastroenterology, Division of Internal Medicine, School of Medicine, University of Ioannina, 451 10, Ioannina, Greece
Insights
Recombinant human erythropoietin (rhEPO) effectively treats anemia in inflammatory bowel disease (IBD) patients. This therapy, combined with iron, shows good results for refractory anemia, improving patient outcomes.
Area of Science:
- Gastroenterology
- Hematology
- Pharmacology
Background:
- Anemia is a frequent complication of inflammatory bowel disease (IBD), negatively impacting patient quality of life and disease management.
- Multiple factors contribute to anemia in IBD, including nutritional deficiencies, medication side effects, hemolysis, and anemia of chronic disease.
- Anemia of chronic disease in IBD involves impaired iron utilization, insufficient erythropoietin (EPO) production, and a blunted bone marrow response to EPO.
Purpose of the Study:
- To evaluate the efficacy and safety of recombinant human erythropoietin (rhEPO) in correcting refractory anemia in IBD patients.
- To explore the potential benefits of rhEPO therapy, such as enabling pre-surgical autologous blood donation and reducing transfusion needs.
Main Methods:
- Review of existing evidence on rhEPO therapy in adult and pediatric IBD patients with refractory anemia.
- Assessment of treatment outcomes, including anemia correction and impact on quality of life.
- Consideration of necessary co-interventions, such as iron supplementation and exclusion of other anemia causes.
Main Results:
- Recombinant human erythropoietin (rhEPO) in combination with iron has demonstrated good results in correcting refractory anemia in both ulcerative colitis (UC) and Crohn's disease (CD) patients.
- rhEPO therapy offers potential advantages, including facilitating autologous blood donation before surgery and minimizing the need for blood transfusions.
- The safety profile of rhEPO in IBD patients appears favorable.
Conclusions:
- rhEPO is a viable and safe therapeutic option for refractory anemia in IBD patients, often requiring concurrent iron supplementation.
- Further large-scale studies are warranted to optimize rhEPO treatment protocols for anemia in IBD.
- Addressing other anemia causes before initiating rhEPO is crucial for successful management.
Abstract:
Anemia is a common problem in inflammatory bowel disease (IBD). It is related to low Karnofsky scores, loss of weight, impaired physical activity, low tolerance to the underlying disease, and a poor growth rate in children. Multiple factors can contribute to the anemia in IBD, such as iron, folic acid or B(12) deficiency, treatment with immunosuppressive drugs or sulfasalazine, hemolysis, and anemia of chronic disease. Anemia of chronic disease is characterized by impaired iron utilization, lower erythropoietin (EPO) production than needed, and a low response of bone marrow erythroid progenitor cells to EPO. In recent years, recombinant human erythropoietin (rhEPO) has been used in combination with iron for the correction of refractory anemia in IBD patients (adults or children) with good results. There is increasing evidence that rhEPO may correct refractory anemia in IBD (both ulcerative colitis (UC) and Crohn's disease (CD)). In addition, such therapy may give IBD patients the opportunity to predonate blood before surgery and to avoid blood transfusions. One must not forget to exclude or correct other causes of anemia in IBD patients before administering rhEPO. Furthermore, the enhancement of erythropoiesis by EPO makes it mandatory to administer oral or intravenous iron supplementation during therapy to meet the increased demand. rhEPO is safe in IBD patients. Further studies with larger numbers of patients are needed to optimize the therapy with rhEPO in the refractory anemia of IBD.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents